ArticleBlood2019
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.
Open access · greenAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis.Annals of hematology · 2024Pooled it
- Alternative splicing and cancer: a systematic review.Signal transduction and targeted therapy · 2021Pooled it
- The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy.Cancer medicine · 2026Article
- Haematopoietic Cells Deficient for Calreticulin or Expressing Its Oncogenic Variants Maintain Functional Antigen Presentation.Journal of cellular and molecular medicine · 2026Article
- A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis.Blood · 2026Article
- Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms.Blood neoplasia · 2026Review
- Platelets Outperform Leukocytes in Transcriptomic Liquid Biopsy Profiling of Myeloproliferative Neoplasms.bioRxiv : the preprint server for biology · 2026Article
- Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.Biomarker research · 2025Review
- Genomic and Transcriptomic Profiling of a Highly VirulentMicroorganisms · 2025Article
- Article
- Article
- Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations.Cancers · 2024Review
- Biological relevance of alternative splicing in hematologic malignancies.Molecular medicine (Cambridge, Mass.) · 2024Review
- Tumor Antigens beyond the Human Exome.International journal of molecular sciences · 2024Review
- Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms.Frontiers in immunology · 2024Article
- Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.Nature genetics · 2023Article
- Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.American journal of hematology · 2023Article
- Review
- MARVEL: an integrated alternative splicing analysis platform for single-cell RNA sequencing data.Nucleic acids research · 2023Article
- Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?Cancers · 2023Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 5 institutions in 3 countries.
Fiorella SchischlikCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-4299-7657
Roland JägerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Felix RosebrockMyeloPro Diagnostics and Research, Vienna, Austria.
Eva HugMyeloPro Diagnostics and Research, Vienna, Austria.
Michael SchusterCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-2975-8969
Raimund HollyCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Elisabeth FuchsCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Jelena D Milosevic FeenstraCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-7420-3298
Edith BognerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Bettina GisslingerDivision of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Martin SchallingDivision of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Elisa RumiDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-7572-9504
Daniela PietraDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Gottfried FischerDepartment for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria; and.
Ingrid FaéDepartment for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria; and.ORCID 0000-0002-7698-5526
Loan VulliardCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-2260-4935
Jörg MencheCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-1583-6404
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.
Anna StengelMLL Munich Leukemia Laboratory, Munich, Germany.
Christoph BockCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-6091-3088
Mario CazzolaDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Heinz GisslingerDivision of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Robert KralovicsCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Austrian Academy of Sciences · ATMedical University of Vienna · ATMunich Leukemia Laboratory (Germany) · DEUniversity of Pavia · ITPoliclinico San Matteo Fondazione · IT
Funding
Austrian Science Fund FWF P 29018
Abstract
Ph-negative myeloproliferative neoplasms (MPNs) are hematological cancers that can be subdivided into entities with distinct clinical features. Somatic mutations in
Indexed as
AgedAntigens, NeoplasmCalreticulinFemaleHumansImmunotherapyMaleMiddle AgedMutationMyeloproliferative DisordersReceptors, ThrombopoietinSequence Analysis, RNATranscriptomeAntigens, NeoplasmCalreticulinCALR protein, humanMPL protein, humanReceptors, Thrombopoietin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.